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Abstract 
Development of new medications is a very lengthy and costly process. Finding novel indications for existing 
drugs, or drug repositioning, can serve as a useful strategy to shorten the development cycle. In this study, we 
present an approach to drug discovery or repositioning by predicting indication for a particular disease based 
on expression profiles of drugs, with a focus on applications in psychiatry. Drugs that are not originally 
indicated for the disease but with high predicted probabilities serve as good candidates for repurposing. This 
framework is widely applicable to any chemicals or drugs with expression profiles measured, even if the drug 
targets are unknown. It is also highly flexible as virtually any supervised learning algorithms can be used.  
We applied this approach to identify repositioning opportunities for schizophrenia as well as depression and 
anxiety disorders. We applied various state-of-the-art machine learning (ML) approaches for prediction, 
including deep neural networks, support vector machines (SVM), elastic net, random forest and gradient 
boosted machines. The performance of the five approaches did not differ substantially, with SVM slightly 
outperformed the others. However, methods with lower predictive accuracy can still reveal 
literature-supported candidates that are of different mechanisms of actions. As a further validation, we showed 
that the repositioning hits are enriched for psychiatric medications considered in clinical trials. Notably, many 
top repositioning hits are supported by previous preclinical or clinical studies. Finally, we propose that ML 
approaches may provide a new avenue to explore drug mechanisms via examining the variable importance of 
gene features.  
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INTRODUCTION 
Development of new medications is a very lengthy and costly process. While investment in research and 
development has been increasing, there is a lack of proportional rise in the number of drugs approved in the 
past two decades, especially for drugs with novel mechanisms of actions 1. There is an urgent need for 
innovative approaches to improve the productivity of drug development. This is particularly true for some 
areas like psychiatry, for which there has been lack of therapeutic advances for some time 2,3. 
  
Finding new indications for existing drugs, an approach known as drug repositioning or repurposing, can 
serve as a useful strategy to shorten the development cycle 4. Repurposed drugs can be brought to the market 
in a much shorter time-frame and at lower costs. With the exponential growth of “omics” and other 
biomedical data in recent years, computational drug repositioning provides a fast, cost-effective and 
systematic way to identify promising repositioning opportunities 4.   
 
In this study we describe a general drug repositioning approach by predicting drug indications based on 
their expression profiles, with a focus on applications in psychiatry. We treat drug repositioning as a 
supervised learning problem and apply different state-of-the-art machine learning methods for prediction. 
Drugs that are not originally indicated for the disease but have high predicted probabilities serve as good 
candidates for repositioning. There are several advantages of this approach. Firstly, the presented approach is 
a general and broad framework that leverages machine learning (ML) methodologies, a field with very rapid 
advances in the last decade. This provides great flexibility and opportunities for further improvement in the 
future as virtually any supervised learning methods can be applied. Newly developed prediction algorithms 
can also be readily incorporated to improve the detection of useful drug candidates. In addition, the method 
described here is widely applicable to any chemical or drugs with expression profiles recorded, even if the 
drug targets or mechanisms of actions are unknown. For example, herbal medicine products may contain a 
mixture of ingredients with uncertain drug targets; even for many known medications [e.g. lithium 5], their 
mechanisms of actions and exact targets are not completely known. If transcriptomic profiling has been 
performed, they can still be analyzed for therapeutic or repositioning potential under the current approach. 
 
There has been increasing interest in computational drug repositioning recently, in view of the rising cost of 
new drug development. Hodos et al.6 provided a comprehensive and updated review on this topic. 
Similarity-based methods (e.g. ref.7-12) represent one common approach, but as noted by Hodos et al., the 
dependence on data in the “nearby pharmacological space” might limit the ability to find medications with 
novel mechanisms of actions. Another related methodology is the network-based approach 13, which typically 
requires data on the relationship between drugs, genes and diseases as well as connections within each 
category (e.g. drug-drug similarities). It can integrate different sources of information but may still be 
constrained by the focus on a nearby pharmacological space and the choice of tuning parameters in network 
construction or inference is often ad hoc6. The present work is different in that we offer a broad framework for 
repositioning and we do not focus on one but many different kinds of learning methods. There is 
comparatively less reliance on known drug mechanisms or the “nearby pharmacological space” as we let the 
different algorithms “learn” the relationship between drugs, genes and disease in their own ways. We note that 
kernel-based ML methods such as support vector machine (SVM) are also based on some sort of similarity 
measures, but here we considered a variety of other approaches and SVM is one of the methods which falls 
under the broader framework of ML for repositioning. For high-throughput omics data, often only a subset of 
genes or input features are relevant and a machine learning approach is able to “learn” which features to 
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consider for repositioning. As we shall discuss later, ML approaches also provide a new avenue to explore the 
mechanisms of different drug classes, by studying the variable importance of input genes. 
 
We are particularly interested in drug repositioning for psychiatric disorders in view of the lack of novel 
treatments in the area. It is worth noting that while psychiatric disorders are leading causes of disability 
worldwide14, there have been limited advances in the development of new pharmacological agents in the last 
two decades or so3. Development of new therapies is also limited by the difficulty of animal models to fully 
mimic human psychiatric conditions15. Investment by drug companies has in general been declining3, and new 
approaches for drug discoveries are very much needed in this field. We will explore repositioning 
opportunities for schizophrenia along with depression and anxiety disorders. Here depression and anxiety 
disorders are analyzed together as they are highly clinically comorbid16,17, show significant genetic 
correlations18, and share similar pharmacological treatments19.  
 
Contributions of this study are summarized below. Firstly, we presented a general approach to drug 
repositioning based on ML methods, leveraging drug expression profiles as predictors. While previous work 20 
has also proposed the use of ML on drug transcriptome profiles for classifying drugs into groups (e.g. 
anti-cancer drugs, cardiovascular drugs, drugs acting on the central nervous system etc.), we focused on drug 
repositioning for particular diseases instead of predicting the big therapeutic groups. Secondly, we have 
performed a comparison of the predictive performances of five state-of-the-art and perhaps most commonly 
employed ML algorithms, including deep neural networks, support vector machines, elastic net, random forest 
and gradient boosted trees. Thirdly, we identified new repositioning opportunities for schizophrenia and 
depression/anxiety disorders, and validated the relevance of the repositioned drugs by showing their 
enrichment among drugs considered for clinical trials, as well as support by previous literature. We also found 
that methods with slightly lower predictive accuracy still reveal literature-supported repositioning candidates 
that are of different mechanisms of actions from the drugs listed by better-performing algorithms. Finally, we 
explored which genes and pathways contributed the most to our predictions, hence shedding light on the 
molecular mechanisms underlying the actions of antipsychotics and antidepressants.  
 
METHODS 
We present a general drug repositioning approach adopting a supervised learning approach. We construct 
prediction models in which the outcome is defined as whether the drug is a known treatment for the disease, 
and the predictors are expression profiles of each drug. Drugs that are not originally known to treat the disease 
but have high predicted probabilities are regarded as good candidates for repositioning.  
 
Drug expression data 
The expression data is downloaded from the Connectivity Map (CMap), which captures transcriptomic 
changes when thee cell lines (HL60, PC3, MCF7) were treated with a drug or chemical21. We downloaded raw 
expression data from Cmap, and performed normalization with the MAS5 algorithm22. Expression levels of 
genes represented on more than one probe sets were averaged. We employed the limma package23 to perform 
analyses on differential expression between treated cell lines and controls. Analyses were performed on each 
combination of drug and cell line, with a total of 3478 instances. Expression measurements were available for 
12436 genes.  Statistical analyses were performed in R3.2.1 with the help of the R package “longevityTools”. 
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Defining drug indications 
Drug indications were extracted from two known resources, namely the Anatomical Therapeutic Chemical 
(ATC) classification system and the MEDication Indication Resource high precision subset (MEDI-HPS)24. 
We focus on schizophrenia as well as depression and anxiety disorders in this study. From the ATC 
classification system, two groups of drugs were extracted, including antipsychotics and antidepressants. On 
the other hand, the MEDI-HPS dataset integrates four public medication resources, including RxNorm, Side 
Effect Resource 2 (SIDER2)25, Wikipedia and MedlinePlus. We used the MEDI high-precision subset 
(MEDI-HPS) which only include drug indications found in RxNorm or in at least 2 out of 3 other sources24. 
This subset achieves a precision of up to 92% according to Wei et al.24.  
 
Machine learning methods 
We employed different state-of-the-art machine learning approaches including deep neural networks (DNN)26, 
support vector machine (SVM)27, random forest (RF)28, gradient boosted machine with trees (GBM)29 and 
logistic regression with elastic net regularization (EN)30 to predict indications. Our data is imbalanced as only 
a minority of the drugs are indicated for schizophrenia or depression/anxiety disorders. We performed both 
unweighted and weighted analyses in this study; in the weighted analysis, class weights are adjusted such that 
the minority group (drugs indicated for the disorder) will receive higher weight to achieve a balance between 
positive and negative instances.  
   
In our unweighted model, DNN was implemented in the python package keras. Hyperparameters were 
chosen by the “fmin” optimization algorithm from “hyperopt”, which employs a sequential model-based 
optimization approach31. The tree-structured Parzen estimator (TPE) was used. The more sophisticated 
hyper-parameter search strategies provided by sequential model-based methods may produce better results 
than simpler approaches (e.g. grid search) when the number of hyper-parameters is large, such as in deep 
learning settings 31. Fifty evaluations were run for each search of optimal hyper-parameters. Dropout and 
mixed L1/L2 penalties were employed to reduce over-fitting. The neural networks consisted of two or three 
layers, with number of nodes selected uniformly from the range [64, 1024]. Dropout percentage was selected 
uniformly from [0.25, 0.75], and L1/L2 penalty uniformly from [1E-5, 1E-3]. Optimizer was chosen from 
“adadelta”32, “adam”33 and “rmsprop”34, and the activation function chosen from “relu”, “softplus” or “tanh”. 
One hundred epochs were run for each model and we extracted the model weights corresponding to the best 
epoch.  
 
We also attempted ‘hyperopt’ for the weighted analysis, however the predictive performance was 
unexpectedly poor due to unclear reasons yet to be revealed. We therefore turned to hyperparameter selection 
with grid search, with some adjustments in the parameter ranges. A two-layer neural network was constructed 
with dropout and mixed L1/L2 to avoid over-fitting. The number of neurons in the first hidden layer was 
selected from {1000, 1500, 2000}, the number in the second layer from {500, 1000, 1500}, dropout rate from 
{0.4, 0.5, 0.6, 0.7, 0.8}, L1/L2 penalty from intervals [-13, -3] and [-9, -8] in log space and the number of 
epochs from [10, 20, 30, 50]. In order to speed up hyperparameter selection, we first chose the number of 
epochs, the best optimizer and activation function (following the same parameter range as described above) 
with other parameters fixed, and then used the best parameters chosen in the first step to find the optimal 
complexity of our neural networks by selecting the number of neurons in each layer, dropout and mixed 
L1/L2 penalties. 
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  SVM, RF and GBM models were implemented in “scikit-learn” (sklearn) in python. Hyper-parameter 
selection was performed by the built-in function GridSearchCV in sklearn. For SVM, we chose radial basis 
function as the kernel. The two hyper-parameters C and gamma were selected from [-5, 2] and [-6, 2] in 
log10-space respectively.  
 
For RF, the number of bagged trees was set to 1000, the maximum number of features used for splitting was 
selected from {800, 1000, 1500, 2000, 3000, 5000} and min_samples_leaf (the minimum number of samples 
required at a leaf node) was selected from {1, 3, 5, 10, 30, 50, 80}. For GBM, the number of boosting 
iterations was selected from a sequence of 100 to 1001 with step size 50, learning rate from {0.005, 0.01, 
0.015, 0.02, 0.03, 0.05}, subsampling proportion from {0.8, 1}, maximum depth of each estimator from {2, 3, 
5, 10} and maximum number of features from {10, 30, 50, 100, 500, 1000}. Finally, the EN model was 
implemented by the R package “glmnet”35. The elastic-net penalty parameter α was chosen from seq(0, 1, 
by=0.1), with other settings following the default.  
 
Nested Cross-validation 
We adopted nested three-fold cross validation (CV) to choose hyper-parameters and evaluate model 
performances. It has been observed that optimistic bias will result if one uses simple CV to compute an error 
estimate for a prediction algorithm that itself is tuned using CV36. Nested CV avoids this problem and is able 
to give an almost unbiased estimate of prediction accuracy36. The inner loop CVs were used to choose the 
parameters that optimized predictive performance. In each outer loop CV we made predictions on the 
corresponding test set using the best model trained from the inner CV loops. To achieve maximum 
consistency in our comparisons, we compared different methods on the same test set in each loop. Note that 
the test sets were not involved in model training or parameter tuning. 
  
Predictive performance measures 
The performances of the machine learning methods were evaluated in the test sets using three metrics, 
including log loss, area under the receiver operating characteristic curve (ROC-AUC) and area under the 
precision recall curve (PR-AUC). Log loss compares the predicted probabilities against the true labels. The 
receiver operating characteristic curve, which plots the sensitivity (i.e. recall) against (1- specificity), is a very 
widely used approach to evaluate predictive performances in biomedical applications. The precision-recall 
curve on the hand plots the precision (i.e. positive predictive value) against the sensitivity (recall). Since 
precision depends on the overall proportion of positive labels, the PR-AUC is also dependent on such 
proportions. Davies et al.37 suggested that the PR curve may give more informative comparisons when 
working with imbalanced data.  
 
Identifying important genes and pathways  
We also performed analyses to reveal the genes which contribute the most to the prediction model. For elastic 
net, we extracted the genes with non-zero coefficient in at least one cross-validation fold, and the resulting 
genes were subject to an over-representation analysis (ORA) (using hypergeometric tests) to reveal the 
pathways involved. For RF and GBM, feature importance was computed using built-in functions in sklearn 
based on Gini importance (i.e. the average decrease in node impurity). We then performed a gene-set 
enrichment analysis (GSEA38) based on the genes together with their respective importance scores (the 
highest score across three folds was taken). For SVM and DNN, there is a lack of widely adopted importance 
measures, so we focused on the rest of ML methods in this part. Pathway analyses were conducted by the 
6 
 
web-based program WebGastalt39. Four pathway databases were considered in our analyses, including KEGG, 
PANTHER, Reactome and Wikipathways.  
 
External validation by testing for enrichment of psychiatric drugs considered for clinical trials 
We then performed additional analyses to assess if the drugs with high predicted probabilities from our 
machine learning models are indeed good candidates for repositioning. Briefly, we tested whether the drugs 
with no known indication for the disease but high predicted probabilities are more likely to be included in 
clinical trials.  
 
In the first step, we filtered off drugs that are known to be indicated for the disease as derived from ATC 
and MEDI-HPS. This is because we are mainly interested in repositioning other drugs of unknown therapeutic 
potential, and that the labels of drug indication (from ATC or MEDI-HPS) have already been utilized in the 
ML prediction steps. Next, we extracted a list of drugs that were included in clinical trials for schizophrenia as 
well as depression and anxiety disorders. The list was derived from clincialTrial.gov and we downloaded a 
pre-complied version from https://doi.org/10.15363/thinklab.d212. 
 
We then tested for enrichment of those drugs listed in clinicalTrial.gov among the top repositioning results. 
We performed an enrichment analysis of “drug-sets”, similar to a gene-set analysis approach widely used in 
bioinformatics40. We performed one-tailed t-tests to assess if the predicted probabilities (derived from machine 
learning models) are significantly higher for psychiatric drugs considered in clinical trials.  
 
RESULTS 
Predictive performance comparison 
Unweighted analysis 
The average predictive performances (averaged over three folds) of different machine learning methods are 
listed in Table 1. When considering log loss as the criteria of interest, SVM gave the best result overall, 
though EN showed the best performance in one of the four datasets. DNN and EN showed quite similar 
predictive performances. RF and GBM were slightly worse than other methods, but the difference was small.  
 
When ROC-AUC was considered as the performance metric, SVM and EN gave similar performances. 
SVM outperformed EN in the schizophrenia datasets, while EN showed better results in the other two datasets. 
The performance of DNN was worse than that of SVM and EN, although the differences were not large. The 
two tree-based methods performed worse especially in the depression/anxiety datasets. 
 
We then considered PR-AUC, which is more sensitive to imbalanced data, as the measure of predictive 
performance. SVM was the best-performing method. EN and DNN followed with very similar performances. 
Consistent with other performance measures, GBM and RF did not perform as well in the depression/anxiety 
datasets, but the performance was more comparable for the schizophrenia datasets.  
 
Weighted analysis 
Compared with unweighted analysis, we observed improvements in predictive performance for several 
methods including GBM, RF and deep learning. SVM and EN performed similarly in general. Considering 
ROC-AUC, deep learning performed the best for depression and anxiety disorders, while RF and EN showed 
highest ROC-AUC for schizophrenia. SVM achieved the best PR-AUC and log-loss compared to other ML 
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approaches.  
 
Enrichment for psychiatric drugs considered in clinical trials  
We further tested whether the top repositioning results are enriched for drugs included in clinical trials for 
psychiatric disorders. As shown in Table 2, we observed significant enrichment of such drugs for both 
schizophrenia and depression/anxiety disorders across all methods in the weighted analysis. In addition, most 
results in the unweighted analysis were also significant. This external validation provides further support to 
the usefulness of our approach in identifying new repositioning opportunities.  
 
Identifying contributing genes and pathways  
Supplementary Tables 1-4 show the top genes as identified by variable importance measures (for RF and 
GBM) and regression coefficients (for EN). The enriched pathways are shown in Table 3 and Supplementary 
tables 5-12. Since the number of genes involved is large, we only highlighted a few top enriched pathways 
here. Interestingly, steroid and cholesterol biosynthesis are among the most significantly enriched pathways 
for drugs against schizophrenia and depression/anxiety. Notably, abnormalities in the 
hypothalamic-pituitary-adrenal (HPA) axis have long been suggested as one of the key pathological 
mechanisms underlying depression41. The steroid (cortisol) synthesis inhibitor metyrapone has been shown to 
be effective for depression in a double-blind randomized controlled trial (RCT)42 and other studies (reviewed 
in ref.43), although another trial failed to show any benefits44. Antidepressants have also been shown to 
regulate glucocorticoid receptor functioning in vivo. On the other hand, neuroactive steroids may be 
implicated in the pathophysiology of schizophrenia45. Cholesterol biosynthesis, including regulation by sterol 
regulatory element-binding protein (SREBP), was frequently top-listed in our pathway analysis. 
Antipsychotics and some antidepressants are associated with metabolic syndrome and weight gain, and 
previous in vitro and in vivo studies have shown lipogenic effects of these drugs as controlled by SREBP 
transcription factors46,47. Interestingly, some studies showed lower cholesterol may be associated with 
suicidality48, depressive symptoms49,50, and poorer cognition in schizophrenia51, but these findings are 
controversial. Whether pathways related to cholesterol synthesis may play a role in the therapeutic effects of 
psychotropic drugs remain a topic for further investigation. Some other pathways are also worth mentioning. 
For example, IGF signaling pathway was significantly enriched under antidepressants. IGF-I has been 
reported to improve depression and anxiety symptoms in clinical samples52, and showed antidepressant-like 
effects in animal models (e.g. ref.53,54). The 5-HT3 signaling pathway was also top-listed under antipsychotics. 
5-HT3 has been proposed as a new drug target and improvements in negative and cognitive symptoms have 
been reported in clinical trials55.  
 
Top repositioning hits and literature support from previous studies 
Table 4 show some of the selected top repositioning candidates with literature support, which will also be 
discussed below. Tables 5 and 6 show the top 15 repositioning hits by DNN and SVM respectively. 
Predictions with the weighted ML models were presented here due to better overall predictive performances. 
More detailed tables showing the top 100 hits for each ML method in both unweighted and weighted analyses 
are presented in Supplementary Tables 13-16. Note that drugs that are known to be indicated for these 
disorders according to ATC or MEDI-HPS were excluded from the lists. We noted overlap in top hits derived 
from different machine learning methods, but some repositioning candidates are unique to one or few ML 
approaches. This suggests that employing a diverse set of ML methods may be advantageous in “learning” 
different potential repositioning candidates. We will chiefly focus on candidates from the top 15 hits for each 
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ML method in the exposition below.  
 
Repositioning candidates for depression/anxiety disorders 
Regarding depression and anxiety disorders, many of the top results are antipsychotics, such as 
trifluoperazine, perphenazine, fluphenazine and thioridazine, among others. Antipsychotics have long been 
used for the treatment for depression56. In earlier studies, phenothiazines (a class of antipsychotic to which 
many of our top hits belong) was observed to produce similar anti-depressive effects as tricyclic 
antidepressants57. Due to the risk of extra-pyramidal side-effects, typical antipsychotics are less commonly 
used these days and second-generation (atypical) antipsychotics are more often prescribed. Meta-analyses 
have shown that atypical antipsychotics are effective as adjunctive or primary treatment for depression58,59. 
Antipsychotics are also commonly prescribed for severe depressive episodes with psychotic symptoms.  
 
A few other drugs on the lists are also worth mentioning. Cyproheptadine (top-listed by SVM, RF, GBM and 
EN) is a 5-HT2 receptor antagonist and was shown to improve depression in a small cross-over trial
60. It was 
also reported that the drug reduced the neuropsychiatric side-effects of the antiviral therapy efavirenz, 
including depressive and anxiety symptoms61. Chlorcyclizine belongs to the phenylpiperazine class and 
numerous antidepressants and antipsychotics also belong to this class62. Pizotifen, listed by EN, is a 5-HT2A/2C 
antagonist which was shown to possess antidepressant effects in a double-blind RCT63. DNN and EN have 
identified histone deacetylase (HDAC) inhibitors including trichostatin A and vorinostat as top repositioning 
hits for depression/anxiety and schizophrenia. HDAC have been implicated in the pathogenesis of psychiatric 
disorders including depression, as reviewed by Fuchikami et al.64. HDAC inhibitors have been reported to 
produce antidepressant-like effects in animal models65,66, although no clinical trials on psychiatric disorders 
were available. Interestingly, in a recent study which employed gene-set analysis on de novo mutations to 
uncover repositioning opportunities, HDAC inhibitors were highlighted as candidates for schizophrenia and 
other neurodevelopmental disorders67.  
 
Another candidate was tetrandrine, a calcium channel blocker top-listed by DNN, RF, GBM and SVM. 
Tetrandrine demonstrated antidepressant-like effects in mice68 in forced swimming and tail suspension tests. 
The drug also increased the concentration of 5-hydroytrytamine (5-HT) and norepinephrine in mice treated 
with reserpine or chromic mild stress, and raised the levels of brain-derived neurotrophic factor (BDNF) in the 
latter case68.   
 
Repositioning candidates for schizophrenia 
With regards to repositioning results for schizophrenia, some of the hits are antidepressants, such as 
protriptyline, maprotiline and clomipramine, among others. Antidepressants are frequently prescribed in 
schizophrenia patients due to possibility of comorbid depression or obsessive-compulsive disorder69. In 
meta-analyses antidepressants were also found to improve negative symptoms of schizophrenia70,71. For the 
antidepressants on the list, maprotiline (listed by RF, GBM, EN, SVM) has been reported to improve negative 
symptoms in chronic schizophrenia patients72 as an adjunctive treatment. Other drug clomipramine (listed by 
DNN, GBM, EN) has been shown to ameliorate not only obsessive-compulsive but also overall schizophrenic 
symptoms in patients with comorbid disorders73. Interestingly, the mood stabilizer valproate was also listed 
among the top (by DNN and SVM). Valproate may improve clinical response when added to antipsychotics, 
although the evidence is mainly based on open RCTs74. The EN algorithm also “re-discovered” spiperone, an 
antipsychotic not listed in ATC or MEDI-HPS, as one of the top repositioning hits.  
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Several other drugs less well-known for psychiatric disorders are also worth mentioning. The selective 
estrogen receptor modulator raloxifene (listed by DNN and EN) was shown to improve schizophrenia 
symptom scores in double-blind RCTs of post-menopausal women75,76. Another drug nordihydroguaiaretic 
acid (listed by DNN, GBM, SVM) has antioxidant properties77 and may be useful in combating oxidative 
stress in schizophrenia78. Pioglitazone, top-ranked by DNN, belongs to the class of thiazolidinediones and has 
anti-diabetic and anti-inflammatory properties. Although this drug was withdrawn due to unexpected adverse 
effects on the liver, our finding suggested that other thiazolidinediones may be useful for schizophrenia. 
Indeed, another drug of the same class known as pioglitazone has been shown to improve negative symptoms 
in schizophrenia patients in a double-blind RCT79. Another RCT also showed improvements in depressive 
symptoms 80. Tretinoin (listed by DNN) is a retinoid and retinoid dysfunction has been linked to 
schizophrenia81,82. Clinical trials with another retinoid (bexarotene) showed some benefits of the drug as an 
add-on agent in schizophrenia. Again retinoid signaling was implicated for schizophrenia in a recent study on 
drug repositioning leveraging de novo mutations67. Felodipine (listed by GBM) is a calcium channel blocker 
and GWAS on schizophrenia and bipolar disorder have revealed many genes related to calcium channels83,84; a 
recent study also suggested concomitant use of CCB and antipsychotics may be more beneficial than 
antipsychotics alone85.  
 
Some hits from the unweighted analysis 
The top repositioning candidates from unweighted analysis for each ML method are listed in supplementary 
tables 13-16. There were a number of overlaps with the candidates from the weighted analysis. Here we 
highlight a few prioritized drugs (that have not been mentioned above) with literature support. Aspirin 
(acetylsalicylic acid) is a non-steroidal anti-inflammatory agent (listed by SVM), which has been shown to 
improve schizophrenia symptoms in a recent meta-analysis of RCTs86. Genistein is a phytoestrogen and can 
bind to estrogen receptors87. An animal study showed that genistein may possess anti-dopaminergic actions88; 
interestingly, clinical studies have shown potential therapeutic benefits of estrogens on schizophrenia86. 
The EN algorithm identified metformin as one of the top repositioning hits for depression/anxiety disorders. 
A study in Taiwan reported that the risk of depression in diabetic patients was reduced by ~60% for those 
given metformin with sulfonylurea89. Another study reported improved depressive symptoms and cognitive 
functions for patients with comorbid diabetes and depression90. Another drug apigenin, top-listed by GBM, 
was supported by a number of in vitro and animal studies for possible antidepressant-like and anxiolytic 
effects91. A clinical trial of oral chamomile (which was standardized to contain 1.2% of apigenin) showed 
benefits for anxiety and depression92,93.  
 
Discussions  
In this study, we have presented a repositioning approach by predicting drug indications based on expression 
profiles. We employed and compared five state-of-the-art machine learning methods to perform predictions. 
We also observed that the top repositioning hits are enriched for psychiatric drugs considered for clinical trials 
and that many hits are backed up by evidence form animal or clinical studies, supporting the validity of our 
approach.  
   
  Concerning the performance of different machine learning classifiers, we have employed five methods in 
total, and all but one (EN) are non-linear classifiers. SVM is a kernel-based learning approach that is widely 
used in bioinformatics. On the other hand, deep learning methods (such as DNN) that are based on the 
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principles of representation learning94 have witnessed rapid advances in the last decade, especially in the field 
of computer vision. While potentially powerful, current successful applications typically require very large 
datasets for training, and we suspect that the relatively modest sample size (N = 3478) of our dataset may have 
limited DNN to achieve the optimal predictive ability. We have used at most two hidden layers in view of the 
moderate sample size, and the complexity of the network may be increased with larger samples, although 
larger samples would lead to greater computational costs. This study shows that deep learning can achieve 
reasonable performance in drug repurposing, and indeed DNN achieved the best ROC-AUC for 
depression/anxiety disorders in the weighted analysis. Given the rapid growth in the area, deep learning 
approaches might be worthy of further investigations. While logistic regression with EN is a linear classifier, 
it performed well overall though lagging behind SVM. The performances of the two tree-based methods (RF 
and GBM) were largely comparable with other methods in the weighted analysis, although they were less 
satisfactory without weighting. Notwithstanding the differences in predictive performances, different 
algorithms are based on diverse model assumptions and principles, and as shown above, methods with slightly 
lower predictive accuracy may still reveal useful repositioning candidates that are of different mechanisms of 
actions.  
 
To the best of our knowledge, this is the first study to employ a comprehensive array of machine learning 
methods on drug expression profiles for drug repositioning of any particular disease; it is also the first 
application in psychopharmacology. This is also the first work to suggest an ML approach to explore the 
molecular mechanisms underlying drug actions. In a related work, Aliper et al. made use of the drug 
transcriptome to predict drug classes e.g. drugs for neurological diseases, drugs for cardiovascular diseases, 
anti-cancer agents etc.20. Here our focus is different and perhaps clinically more relevant in that we directly 
identify repositioning opportunities for a particular disorder. In addition, we concentrated on the study of 
psychiatric disorders, which was not explicitly considered in Aliper et al.20 or other previous works. 
Interestingly, DNN was reported to be the best performing method in their study. However their study20 and 
the present work are not directly comparable as the outcomes studied are different and the evaluation metrics 
also differ. F1 score was used in Aliper et al.20 (although the choice of a cut-off probability for classification 
was not explicitly stated) while we used ROC-AUC, PR-AUC and log loss as performance indicators. 
 
Here we aim to provide a proof-of-concept example showing that the application of machine learning 
methodologies on drug expression profiles may help to identify candidates for repositioning, particularly for 
psychiatric disorders. The approach is intuitive and also highly flexible. Nevertheless, given the variety of 
methods and rapid advances in machine learning and computational drug repurposing, there is still room for 
improvement. Firstly, we only consider drug indications and the drug-induced transcriptomic changes in our 
prediction model. This makes the method very flexible and widely applicable to any compounds or drugs for 
which an expression profile is available. The use of drug transcriptome evades the need of specifying targets 
and knowing the mechanisms of actions, and the approach may even be applicable to a mixture of chemical 
ingredients as may be the case for herbal medicines. However, it is possible that our methods may be further 
improved by incorporating other information such as drug targets and chemical structure, if such information 
is available. As for the prediction algorithm, in our dataset the number of positive labels is small. We tackled 
this problem by adjusting the weighting of positive and negative instances and indeed found improvements for 
several ML approaches. Other methodologies to account for imbalanced data are also possible95, and this may 
be a topic for further explorations. We covered five commonly used algorithms here but this coverage is 
obviously not complete; further studies may benefit from the use of more advanced or recently developed 
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learning methods. We also notice that there is an ongoing effort to expand the coverage of CMap96, and that 
the study with updated full data and documentations have just been released. We are planning to further 
explore the current framework in the expanded dataset.  
 
  It is reassuring to observe that many repositioning hits are supported by previous studies and the results 
enriched for psychiatric drugs considered in clinical trials. However, we stress that further well-designed 
pre-clinical and clinical studies are necessary before the any results can be brought into clinical practice. We 
have also made use of ML methods to explore potentially important genes and pathways that may contribute 
to treatment effects. However, the results require further experimental validations. Computational approaches 
for repositioning and explorations of drug mechanisms, such as ML-based methods, provide a cost-effective 
and systematic way to assess and prioritize drug candidates, and might help to reduce the high failure rates in 
drug development. Given the rising cost in developing a new drug, even a minute reduction in failure rate will 
represent large savings in absolute terms. Further work might involve combining the current approach with 
other computational and experimental methods to further improve the accuracy of drug repositioning.  
 
  It is widely acknowledged that drug development in psychiatry has become stagnant for some years, and 
that traditional approaches to drug discovery has not been as successful as anticipated. On the other hand, the 
past few years have seen an extremely rapid development in ML methods and applications; in this regard, we 
hope that this study will open a new avenue for drug repositioning/discovery, and stimulate further research to 
bridge the gap between ML and biomedical applications especially drug development. The list of 
repositioning candidates might also serve as a useful resource for researchers and clinicians working on 
schizophrenia as well as depression and anxiety disorders, which are illnesses very much in need of new 
therapies.  
 
Supplementary Information is available at 
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Table 1   Average predictive performance of different machine learning models across four datasets in 
unweighted (top) and weighted analysis (bottom) 
Unweighted 
analysis 
  
 
Average Log Loss 
 
MEDI-HPS 
Depression/Anxiety 
ATC antidepressants MEDI-HPS Schizophrenia ATC antipsychotics  
SVM 0.1188 0.0943 0.1018 0.0895 
EN 0.1249 0.0916 0.1097 0.0954 
DNN 0.124 0.0948 0.1111 0.0992 
GBM 0.1293 0.1018 0.1157 0.1039 
RF 0.1294 0.1002 0.1155 0.1013 
     
  Average ROC-AUC 
SVM 0.7141 0.7619 0.7705 0.7755 
EN 0.725 0.779 0.7515 0.7681 
DNN 0.6952 0.7456 0.7533 0.7604 
GBM 0.6536 0.6042 0.7172 0.7433 
RF 0.6315 0.6390 0.7036 0.7501 
     
  Average PR-AUC 
SVM 0.2026 0.1485 0.2973 0.3379 
EN 0.1372 0.1008 0.1586 0.2087 
DNN 0.1447 0.0877 0.1577 0.2156 
GBM 0.0910 0.0417 0.1426 0.1528 
RF 0.1193 0.0639 0.1677 0.1703 
Weighted 
analysis  
 
 
Average Log Loss 
 
MEDI-HPS 
Depression/Anxiety 
ATC antidepressants MEDI-HPS Schizophrenia ATC antipsychotics  
SVM 0.1189 0.0934 0.1022 0.0898 
EN 0.5803 0.5344 0.5028 0.5112 
DNN 0.1309 0.0990 0.1308 0.1098 
GBM 0.1281 0.1032 0.1114 0.0981 
RF 0.1234 0.0943 0.1060 0.0939 
     
  Average ROC-AUC 
SVM 0.7198 0.7718 0.7731 0.7765 
EN 0.6610 0.7394 0.7494 0.7997 
DNN 0.7424 0.7979 0.7410 0.7576 
GBM 0.7155 0.7578 0.7584 0.7794 
RF 0.6890 0.7355 0.7843 0.7801 
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  Average PR-AUC 
SVM 0.2017 0.1510 0.2980 0.3361 
EN 0.0751 0.0896 0.1520 0.2030 
DNN 0.1796 0.1107 0.2278 0.2641 
GBM 0.1800 0.1168 0.2697 0.2780 
RF 0.1771 0.1165 0.2721 0.2707 
 
The learning algorithm with the best performance in each dataset (for each predictive performance measure) is marked in bold.  
ROC-AUC: area under the curve (AUC) of the receiver operating characteristic (ROC) curve; PR-AUC: Average area under 
the curve (AUC) of the precision-recall (PR) curve. 
SVM: support vector machines; EN: logistic regression with elastic net regularization; DNN: deep neural networks; RF: 
random forest; GBM, gradient boosted machines with trees.  
MEDI-HPS: MEDication Indication - High Precision Subset; ATC: Anatomical Therapeutic Chemical classification.  
The drug indications (treated as the outcome variable in prediction) are defined for two kinds of disorders (schizophrenia as 
well as depression and anxiety disorders) using two different sources (MEDI-HPS and ATC), hence a total of four datasets. 
Please refer to the main text for details.  
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Table 2     Enrichment for psychiatric drugs included in clinical trials among the repositioning hits 
  Dataset 
unweighted analysis weighted analysis 
P-value q-value P-value q-value 
SVM 
MEDI-HPS Depression/Anxiety 0.0014 0.0168 0.0011 0.0031 
ATC antidepressants 0.0180 0.0615 0.0039 0.0065 
MEDI-HPS Schizophrenia  0.0205 0.0615 0.0264 0.0299 
ATC antipsychotics 0.0098 0.0588 0.0084 0.0116 
DNN 
MEDI-HPS Depression/Anxiety 0.0105 0.0180  0.0009 0.0030 
ATC antidepressants 0.1369 0.1369  0.0017 0.0043 
MEDI-HPS Schizophrenia  0.0908 0.0991  0.0190 0.0238 
ATC antipsychotics 0.0237 0.0316  0.0021 0.0046 
EN 
MEDI-HPS Depression/Anxiety 0.0022 0.0128  0.0023 0.0046 
ATC antidepressants 0.0032 0.0128  0.0087 0.0116 
MEDI-HPS Schizophrenia  0.0294 0.0353  0.0315 0.0332 
ATC antipsychotics 0.0104 0.0180  0.0033 0.0060 
GBM 
MEDI-HPS Depression/Anxiety 0.0494 0.0988 0.0003 0.0025 
ATC antidepressants 0.0433 0.0988 0.0002 0.0025 
MEDI-HPS Schizophrenia 0.2283 0.2747 0.0269 0.0299 
ATC antipsychotics 0.2482 0.2747 0.0005 0.0025 
RF 
MEDI-HPS Depression/Anxiety 0.0651 0.1116 0.0005 0.0025 
ATC antidepressants 0.2518 0.2747 0.0007 0.0028 
MEDI-HPS Schizophrenia 0.1299 0.1949 0.0427 0.0427 
ATC antipsychotics 0.5232 0.5232 0.0063 0.0097 
 
P-values < 0.05 and q-values <0.05 are in bold.  
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Table 3  Selected enriched pathways based on variable importance of genes in ML models   
Method Name #Gene FDR 
ATC antidepressants and MEDI-HPS depression/anxiety (weighted analysis)   
eNet-ORA_Reactome Cholesterol biosynthesis 7 1.78E-06 
eNet-ORA_Wikipathway Sterol Regulatory Element-Binding Proteins (SREBP) signalling 8 1.73E-04 
eNet-ORA_KEGG Steroid biosynthesis - Homo sapiens (human) 5 2.38E-04 
gbm_KEGG Fat digestion and absorption - Homo sapiens (human) 34 8.95E-03 
gbm_Panther Insulin/IGF pathway-protein kinase B signaling cascade 34 1.05E-02 
rf_Wikipathway Mismatch repair 9 1.38E-01 
rf_Wikipathway ID signaling pathway 16 1.58E-01 
rf_Wikipathway Statin Pathway 25 1.61E-01 
rf_Wikipathway Photodynamic therapy-induced HIF-1 survival signaling 37 1.63E-01 
eNet-ORA_Panther TGF-beta signaling pathway 4 1.70E-01 
gbm_Reactome STING mediated induction of host immune responses 11 2.33E-01 
rf_KEGG Amino sugar and nucleotide sugar metabolism - Homo sapiens (human) 40 2.43E-01 
rf_Wikipathway Phase I biotransformations, non P450 7 2.51E-01 
rf_Wikipathway Target Of Rapamycin (TOR) Signaling 30 2.56E-01 
rf_KEGG Alanine, aspartate and glutamate metabolism - Homo sapiens (human) 28 2.67E-01 
    
ATC antipsychotics and MEDI-HPS schizophrenia (weighted analysis)   
rf_Wikipathway Sterol Regulatory Element-Binding Proteins (SREBP) signalling 64 0.00E+00 
eNet-ORA_Reactome Cholesterol biosynthesis 7 9.33E-05 
eNet-ORA_KEGG Steroid biosynthesis - Homo sapiens (human) 4 2.01E-03 
rf_Wikipathway Statin Pathway 25 2.51E-02 
eNet-ORA_Wikipathway Fatty Acid Beta Oxidation 5 2.98E-02 
eNet-ORA_Reactome Asparagine N-linked glycosylation 15 4.36E-02 
eNet-ORA_KEGG Metabolic pathways - Homo sapiens (human) 37 4.87E-02 
eNet-ORA_Reactome Synthesis of UDP-N-acetyl-glucosamine 3 8.11E-02 
gbm_Panther 5HT3 type receptor mediated signaling pathway 14 8.58E-02 
eNet-ORA_KEGG Citrate cycle (TCA cycle) - Homo sapiens (human) 3 8.96E-02 
gbm_Reactome G1/S-Specific Transcription 18 1.32E-01 
eNet-ORA_Reactome Antigen Presentation: Folding, assembly and peptide loading of class I 
MHC 
4 1.32E-01 
gbm_Panther Androgen/estrogene/progesterone biosynthesis 9 1.40E-01 
rf_Wikipathway Photodynamic therapy-induced unfolded protein response 23 1.42E-01 
eNet-ORA_Reactome COPII (Coat Protein 2) Mediated Vesicle Transport 6 1.44E-01 
We aggregated pathway analysis results from 4 databases, namely KEGG, Reactome, Panther and Wikipathways. Pathways 
that were highly similar were filtered. FDR, false discovery rate; eNet, elastic net; gbm, gradient boosted machine; rf, random 
forest; ORA, over-representation analysis, applicable to elastic net. Only results from weighted analysis are included here.  
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Table 4      Some literature-supported candidates selected from top hits derived from machine learning methods 
(known antipsychotics and antidepressants are not included in this list)  
Drug Method Relationship with disease 
Depression/anxiety 
  
Cyproheptadine SVM, RF, 
GBM, EN 
5-HT2 receptor antagonist, improve depression in a small cross-over trial 
Chlorcyclizine DNN, RF, 
GBM, SVM 
phenylpiperazine group to which many other antidepressants and antipsychotics belong 
Pizotifen  EN 5-HT2A/2C antagonist, positive result in an RCT 
TrichostatinA/Vorinostat DNN, EN HDAC inhibitors may have antidepressant effects as shown in animal models 
Tetrandrine DNN, RF, 
GBM 
CCB; antidepressant-like effects in mice; may increase 5-HT, NE and BDNF 
concentrations 
Apigenin GBM Antidepressant and anxiolytic effects in animal models and in an RCT 
Metformin EN may reduce depression risk among DM subjects  
   
Schizophrenia   
Valproate  DNN, SVM open RCTs reported symptom improvement when used as adjunctive treatment 
Raloxifene DNN, EN improve SCZ symptoms in an RCT of post-menopausal women 
Nordihydroguaiaretic 
acid  
DNN, GBM, 
SVM 
antioxidant; oxidative stress implicated in SCZ 
Pioglitazone DNN Another drug in the same class (pioglitazone) improved SCZ symptoms in RCT 
Tretinoin DNN Retinoid; dysfunction in retinoid signaling may be implicated in SCZ 
Felodipine GBM CCB; CCB added to antipsychotics may be beneficial 
Aspirin                       SVM NSAID; may improve SCZ symptoms as shown in RC 
Genistein                             GBM Phytoestrogen; animal model show possible anti-dopaminergic effects 
Please refer to the main text for detailed discussions and references. As a number of top results were known antipsychotics or 
antidepressants (please refer to the main text for details), these were not presented in the above table.  
SCZ, schizophrenia; RCT, randomized controlled trial; HDAC, Histone deacetylases; CCB, calcium channel blocker; 5-HT, 
serotonin; NE, norepinephrine; BDNF, brain-derived neurotrophic factor; NSAID, non-steroidal anti-inflammatory drugs. 
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Table 5   Top 15 repositioning candidates derived from the deep learning approach 
ATC antidepressants   ATC antipsychotics  
 Drug_cell-line Pred_prob   Drug_cell-line Pred_
prob 
1 homochlorcyclizine_MCF7 0.938   1 metixene_MCF7 0.932 
2 thioridazine_PC3 0.866   2 metixene_PC3 0.926 
3 pimethixene_MCF7 0.830   3 mefloquine_PC3 0.916 
4 levomepromazine_PC3 0.829   4 protriptyline_MCF7 0.907 
5 deptropine_PC3 0.761   5 norcyclobenzaprine_PC3 0.906 
6 fluphenazine_PC3 0.756   6 methylbenzethonium.chloride_MC
F7 
0.895 
7 trifluoperazine_PC3 0.756   7 astemizole_MCF7 0.884 
8 cyproheptadine_PC3 0.736   8 troglitazone_MCF7 0.867 
9 metixene_PC3 0.706   9 clomipramine_MCF7 0.865 
10 tetrandrine_MCF7 0.702   10 nortriptyline_MCF7 0.846 
11 norcyclobenzaprine_MCF7 0.700   11 suloctidil_MCF7 0.835 
12 fluphenazine_HL60 0.695   12 trimipramine_PC3 0.826 
13 flupentixol_PC3 0.691   13 loperamide_MCF7 0.823 
14 norcyclobenzaprine_PC3 0.667   14 perhexiline_MCF7 0.791 
15 loperamide_MCF7 0.667   15 tetrandrine_MCF7 0.788 
       
MEDI-HPS depression/anxiety   MEDI-HPS schizophrenia  
 Drug_cell-line Pred_prob  Drug_cell-line Pred_
prob 
1 trichostatin A_HL60 0.999   1 metixene_PC3 0.945 
2 fluphenazine_MCF7 0.864   2 valproic.acid_MCF7 0.941 
3 promazine_PC3 0.840   3 nordihydroguaiaretic.acid_MCF7 0.939 
4 metixene_PC3 0.817   4 ciclosporin_MCF7 0.926 
5 orphenadrine_MCF7 0.791   5 suloctidil_MCF7 0.922 
6 piperacetazine_PC3 0.757   6 tetrandrine_MCF7 0.908 
7 homochlorcyclizine_MCF7 0.741   7 desipramine_PC3 0.892 
8 fluphenazine_HL60 0.700   8 loperamide_MCF7 0.887 
9 thioridazine_PC3 0.694   9 tretinoin_MCF7 0.874 
10 tetrandrine_MCF7 0.682   10 homochlorcyclizine_MCF7 0.864 
11 fluphenazine_PC3 0.654   11 trimipramine_MCF7 0.857 
12 norcyclobenzaprine_PC3 0.609   12 loperamide_PC3 0.838 
13 clomifene_PC3 0.600   13 profenamine_PC3 0.829 
14 levomepromazine_PC3 0.595   14 raloxifene_MCF7 0.799 
15 haloperidol_MCF7 0.580   15 thiethylperazine_PC3 0.795 
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Table 6   Top 15 repositioning candidates derived from support vector machine  
ATC antidepressants   ATC antipsychotics  
 Drug_cell-line Pred_prob   Drug_cell-line Pred_ 
prob 
1 homochlorcyclizine_MCF7 0.764   1 norcyclobenzaprine_MCF7 0.753 
2 cyproheptadine_MCF7 0.556   2 protriptyline_MCF7 0.667 
3 thioridazine_MCF7 0.420   3 methylbenzethonium.chloride_ 
PC3 
0.611 
4 trifluoperazine_MCF7 0.418   4 astemizole_PC3 0.539 
5 chlorcyclizine_PC3 0.383   5 metixene_MCF7 0.524 
6 levomepromazine_PC3 0.339   6 metixene_PC3 0.517 
7 prochlorperazine_MCF7 0.323   7 nordihydroguaiaretic.acid_HL60 0.488 
8 spiperone_PC3 0.311   8 loperamide_MCF7 0.474 
9 perphenazine_MCF7 0.310   9 suloctidil_MCF7 0.451 
10 pimethixene_MCF7 0.300   10 norcyclobenzaprine_PC3 0.430 
11 trifluoperazine_PC3 0.300   11 maprotiline_PC3 0.416 
12 CP-690334-01_PC3 0.264   12 amitriptyline_PC3 0.391 
13 tetrandrine_MCF7 0.250   13 quinisocaine_PC3 0.366 
14 loperamide_MCF7 0.232   14 mefloquine_PC3 0.364 
15 chlorcyclizine_MCF7 0.228   15 nortriptyline_MCF7 0.341 
       
MEDI-HPS depression/anxiety   MEDI-HPS schizophrenia  
 Drug_cell-line Pred_prob  Drug_cell-line Pred_ 
prob 
1 fluphenazine_MCF7 0.931   1 nordihydroguaiaretic.acid_HL60 0.646 
2 thioridazine_PC3 0.780   2 nordihydroguaiaretic.acid_MCF7 0.615 
3 fluphenazine_HL60 0.780   3 methylbenzethonium.chloride_ 
PC3 
0.574 
4 homochlorcyclizine_MCF7 0.669   4 quinisocaine_PC3 0.550 
5 fluphenazine_PC3 0.455   5 nordihydroguaiaretic.acid_PC3 0.500 
6 cyproheptadine_MCF7 0.446   6 norcyclobenzaprine_MCF7 0.420 
7 perphenazine_MCF7 0.422   7 niclosamide_PC3 0.419 
8 nordihydroguaiaretic 
acid_HL60 
0.356   8 metixene_PC3 0.404 
9 thioridazine_HL60 0.345   9 valproic.acid_PC3 0.404 
10 haloperidol_MCF7 0.331   10 norcyclobenzaprine_PC3 0.401 
11 tetrandrine_MCF7 0.310   11 suloctidil_MCF7 0.395 
12 nordihydroguaiaretic 
acid_PC3 
0.310   12 nortriptyline_MCF7 0.375 
13 metixene_PC3 0.308   13 genistein_PC3 0.372 
14 cyproheptadine_PC3 0.291   14 amitriptyline_MCF7 0.362 
15 metitepine_MCF7 0.287   15 protriptyline_MCF7 0.362 
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